| Autor: |
Mignogna MD; Department of Odontostomatology and Maxillofacial Surgery, University of Naples Federico II, School of Dentistry, Italy., Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology [J Oral Pathol Med] 2000 Apr; Vol. 29 (4), pp. 145-52. |
| DOI: |
10.1034/j.1600-0714.2000.290401.x |
| Abstrakt: |
Systemic corticosteroids remain the mainstay of therapy for pemphigus. Their use has transformed what was almost invariably a fatal illness into one whose mortality is now below 10%. Unfortunately, the high doses and prolonged administration of corticosteroids that are often needed to control the disease result in numerous side effects, many of which are serious or even life-threatening. Sixteen patients affected by oral pemphigus vulgaris were retrospectively examined to illustrate the natural course of the disease and to describe the efficacy of the treatment we utilised. Deflazacort, used with azathioprine, is the steroid of first choice in our therapeutic protocols, while cyclophosphamide and methylprednisolone "pulse therapy" are reserved for cases unresponsive to high doses of oral corticosteroids. In addition, the literature on oral pemphigus vulgaris was reviewed with respect to clinical history, signs and symptoms, management, and treatment outcome. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text